J.P. Morgan Maintains a Buy Rating on SAGE Therapeutics (SAGE)


In a report issued on October 31, Cory Kasimov from J.P. Morgan maintained a Buy rating on SAGE Therapeutics (SAGE). The company’s shares closed on Thursday at $137.55.

According to TipRanks.com, Kasimov is a 2-star analyst with an average return of 0.0% and a 37.8% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Jounce Therapeutics Inc, and Vertex Pharmaceuticals.

Currently, the analyst consensus on SAGE Therapeutics is a Strong Buy with an average price target of $220.25, a 60.1% upside from current levels. In a report issued on October 17, Oppenheimer also initiated coverage with a Buy rating on the stock with a $170 price target.

.

See today’s analyst top recommended stocks >>

Based on SAGE Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $90 million and GAAP net loss of $16.98 million. In comparison, last year the company had a GAAP net loss of $73.72 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts